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Simple Summary: The impact of anemia on the quality of life (QoL) in cancer patients has been
studied previously; however, the cut-off point used to define anemia differed among studies, thus
providing inconsistent results. Therefore, we analysed the clinical impact of anemia on QoL using
the same cut-off point for hemoglobin level to define anemia as that used in ESMO clinical practice
guidelines. This post-hoc analysis aimed to determine the impact of anemia on QoL in cancer patients
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through the European Organization for Research and Treatment of Cancer Quality of life question-
naire version 3.0 (EORTC QLQ-C30) and Euro QoL 5-dimension 3-level (EQ–5D–3L) questionnaire.
We found that cancer patients with anemia had significantly worse QoL in clinical terms. In addition,
anemic patients had more pronounced symptoms than those in non-anemic patients.
Abstract: Anemia is a common condition in cancer patients and is associated with a wide variety
of symptoms that impair quality of life (QoL). However, exactly how anemia affects QoL in cancer
patients is unclear because of the inconsistencies in its definition in previous reports. We aimed to
examine the clinical impact of anemia on the QoL of cancer patients using specific questionnaires.
We performed a post-hoc analysis of a multicenter, prospective, case-control study. We included
patients with cancer with (cases) or without (controls) anemia. Participants completed the European
Organization for Research and Treatment of Cancer Quality of Life questionnaire version 3.0 (EORTC
QLQ-C30) and Euro QoL 5-dimension 3-level (EQ–5D–3L) questionnaire. Statistically significant
and clinically relevant differences in the global health status were examined. From 2015 to 2018,
365 patients were included (90 cases and 275 controls). We found minimally important differences in
global health status according to the EORTC QLQ-C30 questionnaire (case vs. controls: 45.6 vs. 58%,
respectively; mean difference: −12.4, p < 0.001). Regarding symptoms, cancer patients with anemia
had more pronounced symptoms in six out of nine scales in comparison with those without anemia.
In conclusion, cancer patients with anemia had a worse QoL both clinically and statistically.
Keywords: anaemia; neoplasm; quality of life
1. Introduction
Anemia is a global public health problem with major consequences for human health,
as well as for social and economic development [1–3]. In the general population, the
incidence of anemia is approximately 24.8%, affecting 1.62 billion people [4]. Anemia is
common in patients with cancer, particularly among those treated with myelosuppressive
chemotherapy. Estimated prevalence of anemia in cancer patients based on epidemiological
data analysis varies between 30 and 90% [5]. This variability is explained by the different
definitions of anemia, types of malignancy, and the stage of disease [6]. Anemia may
develop as a result of the malignant disease process itself, as a consequence of treatment,
bleeding, nutritional deficiencies, bone marrow damage, tumor infiltration into the bone
marrow, or immunological impairment of erythropoietic response [5–8].
Hemoglobin level is a quantitative variable used for the diagnosis of anemia, and
its cut-off point differs depending on the studies reviewed [9–12]. The World Health
Organization defines the cut-off hemoglobin level for anemia as <12.0 g/dL in women and
<13.0 g/dL in men [9]. Some studies that investigated the relationship between hemoglobin
level and quality of life (QoL) in anemic cancer patients diagnosed anemia in those with
hemoglobin levels <11.0 g/dL [10,11]. In addition, the European Society for Medical
Oncology (ESMO) Clinical Practice Guideline established that cancer patients undergoing
chemotherapy treatment who had hemoglobin level <11 g/dL and iron deficiency should
be administered iron intravenously to correct for this deficiency [12].
Health-related QoL can be defined as a sense of well-being, including physical, emo-
tional, and social dimensions. The use of QoL evaluation has increased significantly in
recent decades [13,14]. Different questionnaires are available for the specific assessment
of QoL in patients with cancer. The European Organization for Research and Treatment
of Cancer Quality of Life Questionnaire version 3.0 (EORTC QLQ-C30) is a reliable ques-
tionnaire that has been used to measure the QoL in patients with cancer [15–17]. The
impact of anemia on QoL has been studied in different populations, including cancer
patients, those with chronic obstructive pulmonary disease, heart failure, and chronic
kidney disease [18–20]. Anemia impairs QoL by causing a variety of symptoms, such as
fatigue, tachycardia, respiratory disorders, and cognitive impairment [21]. Demetri et al.
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reported that increasing hemoglobin levels significantly improved QoL parameters in pa-
tients with cancer undergoing chemotherapy and being treated with recombinant human
erythropoietin [22].
The impact of anemia on QoL in cancer patients has been previously investigated;
however, these studies used different definitions of anemia, thus providing inconsistent
results [15–17,21,23–28]. Therefore, we analyzed the clinical impact on QoL using the same
cut-off point for hemoglobin level to define anemia as that used in ESMO clinical practice
guidelines; this issue was investigated in a heterogeneous population with different tumor
sites and using a control population with similar characteristics. To this end, we performed
a post-hoc analysis of the Quality of Life in Cancer Study (QCa study), which was a
multicenter, prospective, case-control investigation conducted in 13 Spanish hospitals
between June 2015 and January 2018 [29].
2. Results
We obtained data on hemoglobin levels in 86% (365/425) of patients included in the
study (90 cases and 275 controls). Table S1 shows recruitment per center. The mean age
of enrolled participants was 61.4 ± 15.0 years, and 56% were male. The most common
comorbidities were hypertension (37.6%) and dyslipidemia (24.2%). One-third (32.3%) of
the patients had acute symptomatic VTE. All participants had a histologically confirmed
diagnosis of cancer, and the most common types were gastrointestinal (25.2%) and lung
(20.8%) cancers. Metastases were identified in 67.8% of the patients, and 77.5% were
undergoing oncological treatment. The Eastern Cooperative Oncology Group (ECOG)
performance status was 0–1 (90%). Baseline patient characteristics are shown in Table 1.
The marital status, education status, employment status, and gross income of the study
participants are detailed in Table S2.
Table 1. Clinical characteristics of the study patients.
Variable Anemia Present (Cases) Anemia Absent (Controls) Entire Cohort
Male sex, n (%) 43 (47.8%) 161 (58.5%) 204 (55.9%)
Age, years (n = 365); mean ± SD 63.2 (11.8) 60.8 (15.9) 61.4 (15)
Body mass index, kg/m2 (n = 312), mean ± SD 26.2 (4.9) 26.4 (5.3) 26.4 (5.1)
Arterial hypertension (n = 364), n (%) 42 (46.7%) 95 (34.7%) 137 (37.6%)
Dyslipidemia (n = 363), n (%) 23 (25.8%) 65 (23.7%) 88 (24.2%)
Diabetes mellitus (n = 364), n (%) 16 (17.8%) 42 (15.3%) 58 (15.9%)
Asthma (n = 364), n (%) 5 (5.6%) 2 (0.7%) 7 (1.9%)
Acute coronary syndrome (n = 364), n (%) 4 (4.4%) 5 (1.8%) 9 (2.5%)
Stroke (n = 364), n (%) 5 (5.6%) 8 (2.9%) 13 (3.6%)
Chronic kidney disease (n = 364), n (%) 3 (3.3%) 9 (3.3.%) 12 (3.3%)
Smoking (n = 364), n (%) 20 (22.2%) 68 (24.8%) 88 (24.2%)
VTE (n = 365), n (%) 39 (43.3%) 79 (28.7%) 118 (32.3%)
Non-steroidal anti-inflammatory drugs (n = 364),
n (%) 9 (10%) 23 (8.4%) 32 (8.8%)
Statins (n = 364), n (%) 16 (17.8%) 35 (12.8%) 51 (14%)
Active anticancer treatment, n (%) 71 (79.8%) 208 (76.8%) 279 (77.5%)
Central venous catheter, n (%) 13 (14.8%) 62 (22.8%) 75 (20.8%)
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Table 1. Cont.
Variable Anemia Present (Cases) Anemia Absent (Controls) Entire Cohort
ECOG performance status (n = 339)
0, n (%) 16 (19%) 109 (42.7%) 125 (36.9%)
1, n (%) 54 (64.3%) 128 (50.2%) 182 (53.7%)
2, n (%) 13 (15.5%) 13 (5.1%) 26 (7.7%)
3, n (%) 1 (1.2%) 4 (1.6%) 5 (1.5%)
4, n (%) 0 (0%) 1 (0.4%) 1 (0.3%)
Metastasis (n =345), n (%) 58 (68.2%) 176 (67.7%) 234 (67.8%)
Tumor site (n = 365)
Gynecologic, n (%) 20 (22.2%) 22 (8.0%) 42 (12)
Lung, n (%) 17 (18.9%) 59 (21.5%) 76 (20.8%)
Digestive, n (%) 20 (22.2%) 72 (26.2%) 92 (25.2%)
Genitourinary, n (%) 8 (8.9%) 19 (6.9%) 27 (7.4%)
Lymphoma, n (%) 9 (10%) 43 (15.6%) 52 (14.2%)
Other sites, n (%) 16 (17.8%) 60 (21.8%) 76 (20.8%)
Abbreviations: SD: standard deviation; ECOG: Eastern Cooperative Oncology Group.
2.1. Impact of Anemia on Quality of Life in Patients with Cancer
Of the 365 patients included, 97.2% completed the EQ−5D questionnaire (n = 355) and
97% completed the EORTC QLQ-C30 questionnaire (n = 354). When global health status
was evaluated using the EORTC QLQ-C30, patients with anemia showed clinically and
statistically significant differences, showing lower QoL than non-anemic cancer patients
(45.6 vs. 58, respectively; mean difference: −12.4, p < 0.001) (Table 2). These differences
were clinically and statistically significant even after adjustment for the presence or absence
of metastases (43.4 vs. 55.3, respectively; mean difference: −11.9, p < 0.001). Furthermore,
patients with anemia had worse physical functioning (67.2 vs. 78.9, respectively; mean
difference: −11.7, p < 0.001), role functioning (59.4 vs. 71.5, respectively; mean difference:
−12, p < 0.05) and emotional functioning (62.7 vs. 72.2, respectively; mean difference:
−9.8, p < 0.05). Furthermore, anemic patients had more pronounced symptoms (clinically
and statistically) in 6 out of 9 scales compared with those in non-anemic patients. The
affected scales were fatigue (48.0 vs. 35, respectively; mean difference: +13, p < 0.001),
dyspnea (21.6 vs. 14.6, respectively; mean difference: +7.0, p < 0.05), pain (35.5 vs. 23.8,
respectively; mean difference: +11.7, p < 0.001), appetite loss (35.7 vs. 21.5, respectively;
mean difference: +14.2, p < 0.001), nausea and vomiting (20.6 vs. 9.6, respectively; mean
difference: +11.0, p < 0.001), and diarrhea (21.5 vs. 14.4, respectively; mean difference: +7.1,
p < 0.05). However, there were no differences between patients with or without anemia
when using the EQ–5D–3L questionnaire. Figure 1 shows two sections of the violin plot,
indicating differences between cases and controls in the kernel distribution.














Global health status 45.6 58 −12.4 ** 0.78 (0.54; 1.1) −0.48 (−0.23; −0.73)
Physical functioning 67.2 78.9 −11.7 ** 0.71 (0.49; 1) −0.50 (−0.25; −0.75)
Role functioning 59.4 71.5 −12 * 0.86 (0.59; 1.2) −0.37 (−0.12; −0.62)
Emotional functioning 62.7 72.2 −9.8 * 0.67 * (0.46; 0.94) −0.38 (−0.13; −0.63)
Cognitive functioning 80.7 84.1 −3.4 0.86 (0.6; 1.2) −0.14 (−0.39; 0.1)



























Fatigue 48 35 13 ** 0.91 (0.3; 1.3) 0.48 (0.2; 0.7)
Nausea and vomiting 20.6 9.6 11 ** 0.34 ** (0.2; 0.5) 0.52 (0.3; 0.7)
Pain 35.5 23.8 11.7 ** 0.8 (0.5; 1.1.) 0.41 (0.1; 0.6)
Dyspnea 21.6 14.6 7 * 0.75 (0.5; 1) 0.25 (0.1; 0.5)
Insomnia 34.1 30.1 4 0.9 (0.6; 1.3) 0.12 (0.1; 0.4)
Appetite loss 35.7 21.5 14.2 ** 0.6 * (0.4; 0.9) 0.45 (0.2; 0.7)
Constipation 26.6 22.3 4.3 0.87 (0.6; 1.2) 0.14 (0.1; 0.4)
Diarrhea 21.5 14.4 7.1 * 0.57 * (0.4; 0.8) 0.26 (0.01; 0.5)












Index score 0.65 0.73 −0.08 0.88 (0.6; 1.2) −0.24 (−0.4; 0)
Abbreviations: CI: confidence interval. * p < 0.05; ** p < 0.001; 1 EORTC QLQ-C30 functional scale: Higher scores reflect a better health status
and the minimally important difference varies from 6 to 15 points; 2 EORTC QLQ-C30 symptoms scale: Higher scores in the symptoms
scale indicate a reduction in quality of life; 3 EQ–5D–3L: Higher scores reflect a better health status and the minimally important difference
on the EQ–5D questionnaire for patients with malignancies is 0.06–0.08 UI.
Figure 1. Patient data distribution and probability densities within different questionnaires. Patients
with anemia are indicated as “cases” and those without anemia as “controls”. Violin plots for QLQ-
c30 Global Health Status (A) and EQ–5D–3L Index (B). The plots indicate the distribution of the
observed values (dots). The kernel density plot (grey line) represents the probability density function.
Larger sections of the violin plot indicate a higher probability of observation at a given value, whereas
thinner sections correspond to a lower probability.
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2.2. Subgroup Analysis
A stratified analysis was performed according to the sex and location of the tumor.
According the EORTC QLQ-C30 questionnaire, the presence of anemia was found to affect
global health status (with the difference being larger than MID) in men but not in women
(42.5 vs. 59.6%, respectively; mean difference: −17.1, p < 0.001). Only physical functioning
and role functioning were found to be affected in women with anemia. Regardless of sex,
we identified significant differences in the scales related to symptoms with higher scores
in terms of fatigue (49.0 vs. 33.2 in men, respectively; mean difference: 15.8; 48.3 vs. 37.5
in women, respectively; mean difference: 10.8), pain (19.5 vs. 8.8%, in men respectively;
mean difference: 10.7; 21.7 vs. 10.6 in women, respectively; mean difference: 11.1), and
nausea and vomiting (35.8 vs. 22.8 in men, respectively; mean difference: 12.2; 36.0 vs. 25.3
in women, respectively; mean difference: 10.7). Conversely, the EQ–5D–3L questionnaire
showed no significant differences between the sexes (Table S3).
According to tumor location, the patients with gynecologic, gastrointestinal, and lung
cancers had statistically and clinically significant differences (larger than MID) in func-
tional scales of the EORTC QLQ-C30 questionnaire (Table S4). In addition, patients with
gastrointestinal cancer showed significant differences in fatigue, dyspnea, pain, appetite
loss, nausea, and vomiting. Table S5 shows an analysis of symptoms based on the EORTC
QLQ-C30 questionnaire, and the results revealed significant differences (larger than the
MID) in patients with gynecologic and lung cancer (Table S6).
We then analyzed the effect of acute symptomatic VTE on the QoL in patients with
anemia. The functional scales of the EORTC QLO-C30 questionnaire showed significant
differences in physical and role functioning in patients with VTE compared with those
without VTE (60.2 vs. 72.3, respectively; mean difference: −12.1, p < 0.05), (49.5 vs. 66.6,
respectively; mean difference: −17.1, p < 0.05). With respect to symptoms, anemic cancer
patients without VTE scored higher in appetite loss (43.5 vs. 24.5%, respectively; mean
difference: 19.0; Table S7).
3. Discussion
This post-hoc analysis found that the presence of anemia in patients with cancer had a
negative impact on QoL. These results were obtained using the same anemia definition
proposed by the ESMO clinical practice guidelines; additionally, the study cohort consisted
of patients with different tumor locations. The EORTC QLQ-C30 questionnaire showed
that anemia was associated with lower global health status, physical functioning, role
functioning, emotional functioning, as well as higher fatigue, dyspnea, pain, appetite loss,
diarrhea, nausea, and vomiting. A previous study that assessed the impact of anemia on
the QoL in 80 patients with cancer who completed EORTC-QLQ−30 questionnaire sup-
ported these findings, although in this work anemia was defined using hemoglobin level
<6.5 g/dL [15]. Nevertheless, that was a study with a small sample size that represented
a younger population (76.2% were younger than 60 years old), with a predominance of
gynecologic cancer (51.2%) and more severe anemia. Cella et al. developed the Functional
Assessment of Cancer Therapy-Anemia (FACT-An) to evaluate the impact of anemia on
cancer patients. The findings in these studies showed that patients with hemoglobin levels
>12 g/dL reported significantly less fatigue, better physical and functional well-being,
and higher overall QoL than those with hemoglobin levels <12 g/dL [21]. In addition, a
prospective multicenter study performed in Japan enrolled 227 cancer patients to analyze
QoL using the FACT-An. Patients with cancer and hemoglobin <11 g/dL had signif-
icant lower FACT-An scores than those with hemoglobin ≥11 g/dL) (120.2 ± 24.9 vs.
130.5 ± 24.3; p = 0.004) [24]. However, a majority of the patients had lung cancer and were
administered platinum-based chemotherapy, which may have aggravated anemia and
affected QoL. Wedding et al. performed a prospective study to evaluate the association
between anemia, QoL (using the EORTC-QLQ-C30 questionnaire), and functional status
(Karnofsky Performance Status KPS) in 447 patients [17]. The authors found that older
patients (cancer or non-cancer) had worse QoL, but anemia did not have an influence on
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QoL in younger patients with cancer. These findings may be due to the fact that all patients
included were hospitalized and had worse general conditions than those enrolled in an
outpatients setting.
Several placebo-controlled and open-label studies have demonstrated improvements
in QoL through the treatment of anemia with erythropoiesis-stimulating proteins in patients
with cancer [30,31]. In a recent randomized placebo-controlled trial that included 375 pa-
tients with non-myeloid hematologic malignancies, patients who were treated with epoetin
alfa had a significant increase in hemoglobin levels and reported significant improvement
in overall QoL (epoetin alfa + 4.8; placebo −6.0; p = 0.0048), energy levels (epoetin alfa
8.1; placebo −5.8; p = 0.007), and ability to perform daily activities (epoetin alfa +7.5;
placebo −6.0; p = 0.0018) [30]. Hudis et al. performed an open-label, non-randomized,
multicenter study to evaluate the effects of epoetin alfa in patients with stage I-III breast
cancer and baseline hemoglobin levels of ≥10 and ≤14 g/dL. Post-hoc analyses showed
that patients who had baseline hemoglobin ≥10 to ≤12 g/dL had significant improvements
in energy, activity, and overall QoL scores after 12 weeks of epoetin alfa therapy at the final
measurement (p < 0.005) [31]. A recent study suggested that hemoglobin levels >12 g/dL
during erythropoietic therapy have been associated with an increased risk of thrombotic
vascular events; therefore, these treatments are not recommended in cancer patients with
hemoglobin levels >12 g/dL [32].
This study had several strengths. First, although the impact of anemia on the QoL in
cancer patients has been studied previously, it is important to know the impact of anemia
considering the cut-off point indicated in the clinical practice guidelines [12], in a heteroge-
neous population with different tumor sites and using a control population with similar
characteristics that allowed us to obtain direct comparisons of QoL, without resorting to
historical cohorts characterized by different demographic characteristics. According to
the ESMO clinical practice guidelines, which recommend that cancer patients undergoing
chemotherapy treatment and with hemoglobin level <11 g/dL should receive iron treat-
ment, we established the variable anemia at a hemoglobin level <11 g/dL. Second, our
QoL analysis considered minimally important differences, being able to identify clinically
relevant differences that were not only statistically significant without clinical benefit.
Third, the EORTC C−30 questionnaire was found to be a useful and appropriate tool for
analyzing the QoL in patients with anemia.
Our study also had some limitations. First, it was a post-hoc analysis of a case-control
study, and all variables could not be matched. Nevertheless, we recruited 365 patients
with a case:control ratio of 1:3. Second, this study was not initially designed to analyze
the impact of anemia on QoL in cancer patients, and for that reason, other specific tools
were not used to adequately assess anemia. Therefore, in future studies, it would be
interesting to include scales such as FACT-An, which was developed specifically to assess
the impact of anemia in cancer patients [21]. Other tools frequently used in previous
studies of patients with anemia included the LASA and the Functional Assessment of
Cancer Therapy-Fatigue (FACT-F) scale [10,31]. The use of these scales (FACT-An and
FACT-F) would have allowed us to obtain additional information, ultimately representing
a caveat inherent in our study. Moreover, other variables that could affect QoL, such as iron
levels, erythropoietin treatment, blood transfusions, or recent hospitalizations were not
included. It would have been interesting to know the impact on QoL taking these variables
into account; unfortunately, we did not have these data. In this scenario, subgroup analyses
would require a larger sample size to ensure a sufficient statistical power. Finally, we did
not find differences in the generic questionnaire, such as EQ–5D–3L. This may be due to
low statistical power that could be solved by increasing recruitment in future studies.
4. Materials and Methods
4.1. Study Design
This was a post-hoc analysis of QCa. Patients included were divided into two groups:
cases (patients with anemia) and controls (patients without anemia). As previously sug-
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gested by the ESMO Clinical Practice Guideline [12] and other studies on cancer pa-
tients [10,11], anemia was defined as a condition with hemoglobin level <11 g/dL. Several
variable related to anemia were analyzed in this study, including the presence of metasta-
sis, tumor location, and the use of chemotherapy. In this regard, the presence of distant
metastases from solid tumors may invade the bone marrow and disrupt erythropoiesis,
resulting in anemia. Additionally, chemotherapy may cause anemia through a number of
different mechanisms, including stem cell death, oxidant damage to mature hematopoietic
cells, and immune-mediated hematopoietic cell destruction. Finally, tumor localization
may be relevant to the development of anemia in relation to the risk of acute or chronic
blood loss, as in gastrointestinal, genitourinary and gynecologic malignancies [33]. The
complete protocol has been previously published in detail [29,34]. A total of four QoL ques-
tionnaires were evaluated among the included patients, showing that acute symptomatic
VTE adversely affected their QoL. In patients with symptomatic VTE, all questionnaires
were completed within 30 days of the index thrombotic event.
All questionnaires were analyzed anonymously and completed simultaneously to
avoid confounding factors. The Research Ethics Committee of the Virgen del Rocio Hospital,
Sevilla, Spain (code: 0191-N-14) reviewed and approved the study protocol. All of the
eligible patients provided written informed consent.
The objective of this post-hoc analysis was to evaluate the impact of anemia on the
QoL in patients with cancer. With this aim, we compared the global health status between
patients in cases and controls groups using two QoL questionnaires: (1) EORTC QLQ-C30
version 3.0 [35], which is a specific questionnaire for patients with cancer; (2) EQ-5D-
3L [36], which is a generic questionnaire to evaluate QoL. The EORTC QLQ-C30 is a
reliable and valid system that is composed of five functioning scales, three symptom scales,
one global health scale, and six independent items. High scores on the global health scale
and functioning status reflect a better QoL, and high scores on the symptom scale indicate
a reduction in QoL [37,38]. The minimally important difference (MID) on the EORTC
QLQ-C30 questionnaire varied from 6 to 15 points [39–41]. The EQ–5D–3L questionnaire
has been widely used in cancer and anemia studies [42,43]. The questionnaire elicits
information on five aspects of QoL which are scored from 1 (no problems) to 3 (unable
to/extreme problems) [44]. Responses to the five EQ–5D items define a health state for
which an index score can be generated. The index score was anchored at 0 (death) and 1
(full health), with higher scores corresponding to higher health states (scores ranging from
−0.654 to 1). The MID on the EQ–5D questionnaire for patients with malignancies was
0.06–0.08 [45].
4.2. Statistical Analysis
Descriptive statistics are expressed as absolute or relative frequencies (categorical vari-
ables) and means and standard deviations (continuous variables). Continuous data with
an asymmetric distribution are presented as medians and interquartile ranges. The mean,
median and percentage of respondents—along with the minimum/maximum scores—are
presented for each questionnaire. For this post-hoc analysis, we calculated the effect size
(Cohen’s d) and the relative efficiency (RE) to examine the questionnaire performance. The
effect size was obtained using the difference in mean scores divided by the pooled standard
deviation. The effect sizes can vary from mild (0.2) to moderate (0.5) or large (0.8). The RE
statistic was calculated as the ratio of F-statistics in the analysis of variance (ANOVA) tests
of the differences in scores between known groups. A greater efficiency or discrimination
is related to higher F-statistic values. Figure 1 shows a violin plot. In general, violin plots
are a method of plotting numeric data and can be considered as a combination of a box plot
with a kernel density plot. In the violin plot, the same information as in the box plot can
be identified, as follows: median value (black line inside the box) and interquartile range
(edges of the box). The Kernel density estimation (KDE) is a non-parametric approach
for estimating the probability density function of a random variable. In addition, these
plots depict the actual distribution of the observed values (dots in cases and triangles in
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controls). The kernel density plot (grey line) represents the probability density function.
A higher probability of observation at any given value is related to larger sections of the
violin plot.
5. Conclusions
In summary, the results of our study demonstrate that the presence of anemia has
an adverse impact on the QoL in patients with cancer. Therefore, it is crucial to offer
appropriate guidelines for the management and treatment of these patients.
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